title: Comment on: Risk of gastrointestinal perforation in cancer patients receiving ramucirumab: a meta-analysis of randomized controlled trials.
authors.affiliation: a Eli Lilly and Company , Indianapolis , IN , USA.
authors.forename: Andreas
authors.initials: A
authors.lastname: Sashegyi
authors.affiliation: b Eli Lilly and Company , Bridgewater , NJ , USA.
authors.forename: Yawei
authors.initials: Y
authors.lastname: Zhang
authors.affiliation: a Eli Lilly and Company , Indianapolis , IN , USA.
authors.forename: Yong
authors.initials: Y
authors.lastname: Lin
authors.affiliation: b Eli Lilly and Company , Bridgewater , NJ , USA.
authors.forename: Polina
authors.initials: P
authors.lastname: Binder
authors.affiliation: b Eli Lilly and Company , Bridgewater , NJ , USA.
authors.forename: David
authors.initials: D
authors.lastname: Ferry
mesh_terms: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D006801:Humans; D009369:Neoplasms; D016032:Randomized Controlled Trials as Topic; D012306:Risk; D000096662:Ramucirumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000096662:Ramucirumab
keywords: VEGFR/VEGF inhibitor; cancer; gastrointestinal perforation; meta-analysis; ramucirumab; risk